Larimar Therapeutics Change in Accounts Payable 2012-2025 | LRMR

Larimar Therapeutics change in accounts payable from 2012 to 2025. Change in accounts payable can be defined as the increase or decrease in trade payables for the given period.

Larimar Therapeutics Change in Accounts Payable 2012-2025 | LRMR

Larimar Therapeutics change in accounts payable from 2012 to 2025. Change in accounts payable can be defined as the increase or decrease in trade payables for the given period.
Related Stocks
Company NameMarket
Cap
Chugai Pharmaceutical (CHGCY)$72B
Zoetis (ZTS)$69.3B
Takeda Pharmaceutical (TAK)$47.7B
Daiichi Sankyo, - (DSNKY)$45.3B
BeOne Medicines - (ONC)$33.5B
Sandoz Group AG (SDZNY)$27.7B
Summit Therapeutics (SMMT)$17.6B
Merck (MKKGY)$16.4B
Shionogi (SGIOY)$14.6B
Neurocrine Biosciences (NBIX)$13.8B
United Therapeutics (UTHR)$13.7B
IPSEN (IPSEY)$11.4B
Orion OYJ (ORINY)$11.2B
Madrigal Pharmaceuticals (MDGL)$9.7B
Eisai (ESAIY)$8.9B
Corcept Therapeutics (CORT)$7.3B
Stevanato Group S.p.A (STVN)$7B
Grifols, S.A (GRFS)$6.9B
Ionis Pharmaceuticals (IONS)$6.8B
Ono Pharmaceutical (OPHLF)$5.7B
Hikma Pharmaceuticals Plc (HKMPF)$5.4B
Soleno Therapeutics (SLNO)$3.6B
AMNEAL PHARMACEUTICALS, INC (AMRX)$3B
Crinetics Pharmaceuticals (CRNX)$2.9B
NewAmsterdam Pharma (NAMS)$2.7B
Hypermarcas (HYPMY)$2.7B
Procaps Group, S.A (PROCF)$2.6B
Catalyst Pharmaceuticals (CPRX)$2.5B
Centessa Pharmaceuticals (CNTA)$2.2B
Ocular Therapeutix (OCUL)$2.1B